

## C-Path Announces Jennifer Kendra as New Vice President of Strategic Partnerships

### New Leadership to Drive Expansion of Collaborative Initiatives and Fundraising Strategies at C-Path

**TUCSON, Ariz., January 23, 2025** — [Critical Path Institute® \(C-Path\)](#) today announced the appointment of Jennifer Kendra as the new Vice President of Strategic Partnerships.

With a robust career spanning over two decades in strategic planning, partnership development, and executive leadership, Kendra is uniquely positioned to guide C-Path in its work to broaden collaborative initiatives, maximize resources, and further execute the Institute's mission. Her proven expertise in exceeding organizational goals and fostering enduring partnerships will play a critical role in the expansion of C-Path's leadership in drug development.

In her new role, Kendra will direct the Office of Development and be responsible for philanthropic and corporate fundraising, enhancing strategic partnerships, and overseeing major giving initiatives. She will identify and cultivate new collaborative opportunities, strengthen relationships with existing partners, and spearhead new partnerships designed to enhance C-Path's impact on accelerating drug development. Her strategic vision will be focused on maximizing the potential of C-Path's collaborations to facilitate innovations that can significantly advance patient care.

"We are very excited to welcome Jennifer to our leadership team," said C-Path CEO Klaus Romero, M.D., M.S., FCP. "Her exceptional ability to build strategic relationships and drive growth is ideally suited for our mission. Jennifer's leadership will be instrumental in propelling C-Path's initiatives forward, at a time when collaborative innovation is more crucial than ever."



Kendra expressed enthusiasm about her new role, saying, "I am honored to join C-Path, an organization at the forefront of fostering collaborative efforts to speed drug development. The chance to lead and expand our strategic partnerships excites me, and I am eager to contribute to transformative projects that will significantly impact global health outcomes."

Kendra's appointment is effective immediately. She will focus on leveraging C-Path's existing capabilities while exploring new avenues to drive innovation in drug development. Her appointment marks a clear commitment by C-Path to continue advancing as a leader in the development of innovative health solutions, maintaining alignment with the organization's ambitious goals.

### About Critical Path Institute

Founded in 2005, as a public-private partnership in response to the [FDA's Critical Path Initiative](#), Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. **C-Path's mission is to lead collaborations that advance better treatments for people worldwide.** Globally recognized as a

pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit [c-path.org](http://c-path.org).

**Media Contacts:**

Roxan Triolo Olivas  
C-Path  
520.954.1634  
[rolivas@c-path.org](mailto:rolivas@c-path.org)

Kissy Black  
C-Path  
615.310.1894  
[kblack@c-path.org](mailto:kblack@c-path.org)